SLC5A2 and chronic kidney disease: Along with their glucose-lowering effect, various beneficial pleiotropic effects in SGLT2 inhibitors have been demonstrated in previous trials, i.e., the EMPA-Reg outcome, CREDENCE, and DAPA-CKD [70,71,72,73].